|
Andrew Dahlem was named the vice president of toxicology drug disposition pharmacokinetics and Lilly Research Laboratories in Europe at Lilly in January 2003. He is also a member of the senior management council. He had been vice president of drug disposition pharmacokinetics discovery operations and LRL European operations since December 2001.
He received his bachelor of science degree in wildlife biology from The Ohio State University in 1982 and a doctor of philosophy degree in toxicology from the University of Illinois at Urbana-Champaign in 1989.
Dahlem joined Lilly in 1990 as a senior pharmacologist. He became head of biochemical toxicology in 1992. He was named director of drug disposition and biochemical (investigative) toxicology in 1993. He was promoted to executive director for toxicology and drug disposition in 1998 and he assumed responsibility for LRL in Europe in 1999 and for discovery operations in 2000.
He is a member and past president of the Indianapolis/Cincinnati Discussion Group of the American Association of Pharmaceutical Scientists and a member of the International Society for the Study of Xenobiotics.
Dahlem was the recipient of the Joseph O. Alberts Award for the outstanding graduate researcher in the College of Veterinary Medicine and a member of the Sigma Xi Honor Society. He also serves as adjunct professor of toxicology in the College of Veterinary Medicine of both Purdue University and the University of Illinois at Urbana-Champaign. | 